Towards the end of the interview he indicates the method of delivery is one important factor in patients' preference for newer biologics over the original infliximab (noting that infliximab must be delivered intravenously by a medical professional, whereas other drugs can be administered by the patient themself at home):
100% of patients who had received both intravenous and subcutaneous anti-TNF therapy preferred the subcutaneous route. The main reasons given for this preference included that the infusions were painful as well as the autonomy that subcutaneous administration provided.